Let people try gelsolin, a drug in which I'm financially invested!
We need new drugs to fight COVID-19 and other diseases. But our government's approval process makes that too hard.
This year's pandemic got regulators to say they'll speed the approval process. The FDA adopted Emergency Use Authorization to speed up approval of some tests, medical equipment and ventilators.
But that's not enough.
I know about the FDA's rules because my older brother, Dr. Thomas Stossel, discovered something that might save a lot of lives.
Doing medical research at Harvard, he found a protein in our blood that helps reduce excess inflammation. He named the protein gelsolin.
Some inflammation is useful. Our own immune system creates it to fight off diseases.
But excess inflammation kills.
With COVID-19, "what usually kills the patient is not the virus," explains Dr. Mark DiNubile in my new video. "As the patients get sicker, often the virus is disappearing. It's the over-exuberant, excessive, immune reaction that's destroying the lung."
DiNubile was once my brother's student and partner. Now, he speaks for Tom because, several months ago, Tom died of a sudden heart attack. DiNubile will carry on Tom's work.
So will I. Suddenly, I'm an investor and on the board of their biotech company, BioAegis, which hopes to give supplemental gelsolin to people with diseases like pneumonia, sepsis and the coronavirus.